Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection
Articles > Article · 2019
Authors: NİLAY DANIŞ, Hüseyin TÖZ, Nalan Gülşen ÜNAL, Mümtaz YILMAZ, İlker TURAN, Fulya GÜNŞAR, Abdullah Zeki KARASU, Galip ERSÖZ, Mehmet ÖZKAHYA, Ulus Salih AKARCA
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI Expanded, International, 2019, vol 30, pp 695-701
Summary
Background/Aims: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the present study was to investigate the efficacy and safety of PrOD in RT patients with hepatitis C virus (HCV) infection in a single center real-life experience.